ENTRADA THERAPEUTICS, INC. Cash and Restricted Cash
ENTRADA THERAPEUTICS, INC. (TRDA) had Cash and Restricted Cash of $102.57 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $102.57M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $79.74M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $94.34M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $97.24M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $102.57M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $79.74M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $94.34M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $97.24M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $76.43M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $71.79M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $105.16M 10-Q · filed 2026-08-05 |
| 2024-09-30 | $82.00M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $189.20M 10-Q · filed 2025-08-06 |
| 2024-03-31 | $72.39M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $71.55M 10-K · filed 2026-02-26 |
| 2023-09-30 | $55.83M 10-Q · filed 2024-11-05 |
| 2023-06-30 | $83.69M 10-Q · filed 2024-08-13 |
| 2023-03-31 | $231.60M 10-Q · filed 2024-05-07 |
| 2022-12-31 | $49.11M 10-K · filed 2025-02-27 |
| 2022-09-30 | $57.26M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $94.82M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $88.59M 10-Q · filed 2023-05-10 |
| 2021-12-31 | $291.06M 10-K · filed 2024-03-13 |
| 2021-09-30 | $122.17M 10-Q · filed 2022-11-07 |
| 2021-06-30 | $136.95M 10-Q · filed 2022-08-11 |
| 2021-03-31 | $146.19M 10-Q · filed 2022-05-12 |
| 2020-12-31 | $39.05M 10-K · filed 2023-03-06 |
| 2020-09-30 | $46.97M 10-Q · filed 2021-12-09 |
| 2019-12-31 | $16.84M 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |